111 In-DTPA- d -Phe −1 -Asp 0 - d -Phe 1 -octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111 In-DTPA- d -Phe 1 -octreotide
Authors:
- 1 November 2017
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 54, 18-26
Abstract
No abstract availableKeywords
Funding Information
- Grants-in-Aid for Young Scientists (B) (24791329, 15K19810)
This publication has 27 references indexed in Scilit:
- Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)Theranostics, 2012
- Radiopeptide Imaging and Therapy in EuropeJournal of Nuclear Medicine, 2011
- Radiopeptide Imaging and Therapy in the United StatesJournal of Nuclear Medicine, 2011
- Peptide receptor expression in GEP-NETVirchows Archiv, 2007
- Expression of Somatostatin Receptor Subtypes 1 to 5 in Tumor Tissue and Intratumoral Vessels in Malignant Endocrine Pancreatic TumorsMedical Oncology, 2003
- Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligandsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Expression of peptide receptors in human endocrine tumours of the pancreas.Gut, 1997
- Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan)Seminars in Nuclear Medicine, 1995
- In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsLife Sciences, 1991